Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
If antidepressants have not helped, this page explains why your brain may resist them and outlines new medically approved and experimental paths to care. Drivers can include inflammation, glutamate and circuit changes, genetics, or missed conditions, and next-line options include esketamine (Spravato), TMS, ECT, and in select cases VNS.
There are several factors to consider: how to get access to experimental depression meds through clinical trials or expanded access, when off-label care is appropriate, what to confirm in your diagnosis, and what to document from prior trials; see the complete details below to choose the right next step with a psychiatrist.
If you've tried antidepressants and still feel stuck, you are not alone. According to the National Institute of Mental Health, millions of adults live with major depressive disorder, and up to one-third do not respond fully to first-line medications. This is often called treatment-resistant depression (TRD).
It can feel frustrating and discouraging. But there are real biological reasons why your brain may not respond to standard treatment — and there are medically approved and emerging options worth discussing with a doctor.
Below, we break down why depression medications sometimes don't work, what newer treatments exist, and how to get access to experimental depression meds safely and responsibly.
Most common antidepressants (like SSRIs and SNRIs) work by increasing levels of serotonin, norepinephrine, or dopamine. But depression is more complex than just "low serotonin."
Here's why medications may not work for some people:
Depression involves:
If your depression is driven more by inflammation or glutamate imbalance than serotonin, standard SSRIs may not be enough.
Some people metabolize medications too quickly or too slowly due to liver enzyme differences (like CYP450 variations). This can make drugs less effective or cause more side effects.
Conditions like:
can mimic or worsen depression. If the root issue isn't addressed, antidepressants alone may fail.
Long-term stress can physically reshape brain circuits. Medication may help, but therapy or brain-based interventions may also be needed.
If you're unsure whether what you're experiencing is actually depression or something else, you can use Ubie's free AI-powered Depression symptom checker to get personalized insights about your symptoms in just a few minutes—many people find it helpful before their doctor visit.
If you haven't responded to standard medications, you are not out of options. Several newer treatments are FDA-approved or medically recognized for treatment-resistant depression.
Esketamine is a nasal spray derived from ketamine. Unlike traditional antidepressants, it works on the glutamate system, which affects brain plasticity.
What makes it different:
Esketamine is FDA-approved for treatment-resistant depression and depressive symptoms with suicidal thoughts.
TMS is a non-invasive procedure that uses magnetic pulses to stimulate underactive brain areas involved in mood regulation.
Key facts:
TMS is often considered when at least one antidepressant has failed.
ECT has been used for decades and remains one of the most effective treatments for severe depression, especially when:
While the name sounds intimidating, modern ECT is done under anesthesia and is carefully monitored.
VNS involves an implanted device that stimulates the vagus nerve to regulate mood circuits. It is FDA-approved for chronic, treatment-resistant depression, though it is less commonly used.
If approved treatments have not worked, you may wonder how to get access to experimental depression meds or therapies still in development.
Here are medically supervised pathways.
One of the safest ways to access experimental depression medications is through a regulated clinical trial.
Clinical trials are:
Common experimental areas include:
To pursue this route:
Never pursue unregulated or overseas "experimental" treatments without physician guidance.
In rare cases, patients with serious or life-threatening depression may qualify for Expanded Access programs, sometimes called compassionate use.
This pathway:
It is not common, but it is possible in severe cases.
Doctors may legally prescribe FDA-approved medications "off-label" if evidence supports their use in depression.
Examples sometimes considered:
This is not experimental in the illegal sense — but it does require close psychiatric supervision.
If you are seriously considering new or experimental care, follow these steps:
Before pursuing advanced treatment:
Misdiagnosis is a common reason treatment fails.
Most advanced options require proof that:
Keep records of what you've tried.
Psychiatrists are trained in:
Use clear language, such as:
Doctors expect these questions.
When seeking experimental care, avoid:
Experimental does not mean unsafe — but it must be medically supervised.
If you have:
This is a medical emergency. Speak to a doctor immediately or seek emergency care. Advanced treatments like ECT or esketamine may be urgently appropriate in those situations.
Do not wait.
It's important not to sugarcoat this:
Treatment-resistant depression can be difficult. It sometimes requires multiple approaches. There is no single universal cure.
But there are more options available today than at any point in history.
Research into:
is expanding rapidly.
If standard medications haven't worked, that does not mean you are beyond help. It may simply mean your depression requires a different biological approach.
If you're still depressed after trying medication:
You may also benefit from starting with a free, confidential symptom check for Depression to clarify your current symptom pattern before your next appointment.
Most importantly: speak to a doctor about anything that could be serious or life threatening. Depression is a medical condition — and it deserves real medical care.
You are not weak.
You are not failing treatment.
You may simply need a different path forward.
(References)
* Coffin M, Dziubak A, Young AH, Juruena MF. Treatment-resistant depression: Current understanding and future directions. World J Biol Psychiatry. 2021 Jul;22(5):332-343. doi: 10.1080/15622975.2020.1866415. Epub 2021 Jan 12. PMID: 33433229.
* Rush AJ, Zisook S. Treatment-Resistant Depression: A Review of Pathophysiology and Novel Treatment Approaches. J Clin Psychiatry. 2023 Feb 1;84(1):22nr14674. doi: 10.4088/JCP.22nr14674. PMID: 36730248.
* McIntyre RS, Subramaniapillai M, Cha DS, Lee Y, Gill H, Al-Dhaheri S, Muzerengi S, Syeda SN, Phan L, Mansur RB, Rosenblat JD. Novel Approaches in the Treatment of Resistant Depression: A New Era in the Therapeutic Landscape. CNS Drugs. 2020 Mar;34(3):289-311. doi: 10.1007/s40263-020-00702-w. PMID: 32080775.
* Trivedi MH, Daly E, D'Souza DC. Efficacy and Safety of Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression: A Systematic Review. Prim Care Companion CNS Disord. 2021 Apr 22;23(2):20nr02777. doi: 10.4088/PCC.20nr02777. PMID: 33890919.
* Daskalakis ZJ, D'Urzo K, Knyahnytska Y, Khullar A, Rajji TK, Mulsant BH, Blumberger DM, Sinyor M, Remondino M, Tormos-Muñoz E, Barr M, D'Souza R, Feffer T. Neuromodulation for treatment-resistant depression: A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2021 Jun 1;82(3):20r13643. doi: 10.4088/JCP.20r13643. PMID: 34106579.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.